Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | MTR | Q99707 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410544 | 0.84 | TACR1 (0.62) | TACR1 | |
| Hydrochloric Acid SCHEMBL6407071 | 0.82 | TACR1 (0.63) | TACR1 | |
| SCHEMBL6405969 | 0.78 | TACR1 (0.52) | TACR1SIGMAR1 | |
| SCHEMBL6408363 | 0.78 | TACR1 (0.58) | TACR1 | |
| SCHEMBL14198386 | 0.77 | BACE1 (0.50) | CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL6412492 | 0.76 | TACR1 (0.72) | TACR1 | |
| SCHEMBL6410865 | 0.75 | TACR1 (0.66) | TACR1 | |
| SCHEMBL14232131 | 0.74 | BACE1 (0.48) | CYP3A4CYP1A2CYP2D6KCNA3SIGMAR1 | |
| SCHEMBL6406374 | 0.73 | TACR1 (0.76) | TACR1SIGMAR1 | |
| SCHEMBL11475684 | 0.68 | CA1 (0.64) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885OPRM1 35/4885OPRL1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.